Brief: Transgene Announces Results From Clinical Study Of TG4001 In Combination With Avelumab

Transgene SA

27/10/2020 06:35

Oct 27 (Reuters) - Transgene SA  TRNG.PA :
    * ANNOUNCES DETAILED RESULTS FROM CLINICAL STUDY OF TG4001
IN
COMBINATION WITH AVELUMAB IN ADVANCED HPV-POSITIVE CANCERS
    * IN PATIENTS WITHOUT LIVER METASTASES, AN ORR OF 34.8% AND
A
MEDIAN PROGRESSION-FREE SURVIVAL (PFS) OF 5.6 MONTHS WERE
ACHIEVED.
    * COMBINATION OF TG4001 AND AVELUMAB DEMONSTRATES ANTI-TUMOR
ACTIVITY (23.5% OVERALL RESPONSE RATE (ORR)) IN PATIENTS WITH
PREVIOUSLY TREATED RECURRENT AND/OR METASTATIC HPV-RELATED
CANCERS
    * TREATMENT INDUCED HPV-SPECIFIC T-CELL RESPONSES AND WAS
ASSOCIATED WITH INCREASED LEVELS OF IMMUNE CELL INFILTRATION IN
TUMORS AND EXPRESSION OF GENES ASSOCIATED WITH ACTIVATION OF
IMMUNE SYSTEM
    * THESE RESULTS WARRANT FURTHER CONFIRMATION IN A LARGER
CONTROLLED RANDOMIZED STUDY

Source text for Eikon:  ID:nBw9sB0jGa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))